Jump to main content
Jump to site search

Issue 22, 2015
Previous Article Next Article

Thioimidazoline based compounds reverse glucocorticoid resistance in human acute lymphoblastic leukemia xenografts

Author affiliations

Abstract

Glucocorticoids form a critical component of chemotherapy regimens for pediatric acute lymphoblastic leukemia (ALL) and the initial response to glucocorticoid therapy is a major prognostic factor, where resistance is predictive of poor outcome. A high-throughput screen identified four thioimidazoline-containing compounds that reversed dexamethasone resistance in an ALL xenograft derived from a chemoresistant pediatric ALL. The lead compound (1) was synergistic when used in combination with the glucocorticoids, dexamethasone or prednisolone. Synergy was observed in a range of dexamethasone-resistant xenografts representative of B-cell precursor ALL (BCP-ALL) and T-cell ALL. We describe here the synthesis of twenty compounds and biological evaluation of thirty two molecules that explore the structure–activity relationships (SAR) of this novel class of glucocorticoid sensitizing compounds. SAR analysis has identified that the most effective dexamethasone sensitizers contain a thioimidazoline acetamide substructure with a large hydrophobic moiety on the acetamide.

Graphical abstract: Thioimidazoline based compounds reverse glucocorticoid resistance in human acute lymphoblastic leukemia xenografts

Back to tab navigation

Supplementary files

Article information


Submitted
18 Apr 2015
Accepted
23 Apr 2015
First published
23 Apr 2015

Org. Biomol. Chem., 2015,13, 6299-6312
Article type
Paper
Author version available

Thioimidazoline based compounds reverse glucocorticoid resistance in human acute lymphoblastic leukemia xenografts

C. E. Toscan, M. Rahimi, M. Bhadbhade, R. Pickford, S. R. McAlpine and R. B. Lock, Org. Biomol. Chem., 2015, 13, 6299
DOI: 10.1039/C5OB00779H

Social activity

Search articles by author

Spotlight

Advertisements